Roche reported the latest 72-week data from two Phase III trials, BALATON and COMINO, in which its bispecific antibody Vabysmo (faricimab) demonstrated to be effective in treating macular oedema due to branch and central retinal vein occlusion (BRVO and CRVO).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,